±èÅÂȯ ¸íÀÇ

¸¸¼º ôÃß¿°ÁõÀ» Ư¡ÀÎ °­Á÷ôÃß¿° Àü¹®°¡

±èÅÂȯ ¸íÀÇ

  • ¼Ò ¼Ó
    ÇѾç´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú
  • Àü¹®ºÐ¾ß
    °­Á÷ôÃß¿°, ôÃß°üÀý¿°, ·ù¸¶Æ¼½º°üÀý¿°

·ù¸¶Æ¼½º ÁúȯÁß ÃµÀå°üÀýÀÇ ¿°ÁõÀ» ½ÃÀÛÀ¸·Î ¸¸¼ºÀûÀΠôÃß °­Á÷À» ÀÏÀ¸Å°´Â °­Á÷ôÃß¿°ÀÇ Àü¹®°¡·Î ÇöÀç±îÁö 30¿©³â °­Á÷ôÃß¿°, ôÃß°üÀý¿° Áø·áÇÔ. ±¹³» ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ¿¬±¸ »Ó ¾Æ´Ï¶ó ±¹Á¦ Àü¹®°¡¿Í ÇÔ²² °­Á÷ôÃß¿°ÀÇ À¯Àü, º´ÀDZâÀü ¹× Ä¡·á¿¡ ´ëÇÑ ´Ù¼öÀÇ ¿¬±¸ °æÇèÀÌ ÀÖ½¿

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ÇѾç´ë ÀÇ´ë Çлç
  • ÇѾç´ë ÀÇ´ë ¼®»ç
  • °í·Á´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ÇѾç´ëÇб³ ·ù¸¶Æ¼½ºº´¿ø º´¿øÀå

¼ö»ó³»¿ª

Awards List
  • ·ù¸¶Æ¼½ºÇÐȸ Çмú»ó
  • ¿¬±¸Àç´Ü ¿ì¼ö»ó
  • ÇѾç´ëÇб³ Çмú»ó ¹× ¼®Çлó

ÇÐȸȰµ¿

Academic activities
  • 2014 ~ 2018´ëÇÑ ·ù¸¶Æ¼½ºÇÐȸ Ãѹ«ÀÌ»ç
  • 2018 ~ 2020´ëÇÑ ·ù¸¶Æ¼½ºÇÐȸ ±âȹÀÌ»ç
  • 2020 ~ 2022´ëÇÑ ·ù¸¶Æ¼½ºÇÐȸ ÀÌ»çÀå
  • 2021 ~ ÇöÀçÇѾç´ëÇб³ ·ù¸¶Æ¼½ºº´¿ø º´¿øÀå
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö Ann Rheum Dis
Á¦ ¸ñ Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Ann Rheum Dis
Á¦ ¸ñ Prevalence of comorbidities and evaluation of their screening in spondyloarthritis
¹ßÇ¥³âµµ 2016 ¹ßÇ¥Áö Ann Rheum Dis
Á¦ ¸ñ The presence of peripheral arthritis delays spinal radiographic progression in ankylosing spondylitis
¹ßÇ¥³âµµ 2014 ¹ßÇ¥Áö rheumatology
Á¦ ¸ñ Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1)
¹ßÇ¥³âµµ 2019 ¹ßÇ¥Áö Lancet
Á¦ ¸ñ Ixekizumab Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
¹ßÇ¥³âµµ 2020 ¹ßÇ¥Áö Lancet
Á¦ ¸ñ Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2)
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Lancet

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

°­Á÷ôÃß¿°ÀÇ ÀÓ»ó ¹× Ä¡·á, °­Á÷ôÃß¿° ¹× ôÃß°üÀý¿°ÀÇ º´ÀÎ ¿¬±¸

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

±×µ¿¾È ¿¬±¸ ¹× °æÇèÀ» ±â¹ÝÀ¸·Î ȯÀÚ¸¦ Ä¡·áÇϰí ÀÖ½À´Ï´Ù. ²ÙÁØÇÑ Ä¡·á¿Í Ä¡·áµÉ ¼ö ÀÖ´Ù´Â ÀڽۨÀÌ ÀÖÀ¸¸é ¸¸¼ºÁúȯÀ» ±Øº¹ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

°­Á÷ôÃß¿°À» Æ÷ÇÔÇÑ ·ù¸¶Æ¼½ºÁúȯÀÌ ¸¸¼ºÁúȯÀ̶ó ÁÁ¾ÆÁú ¼ö ÀÖ´Ù´Â ¹ÏÀ½°ú ²ÙÁØÇÑ Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ ³ë·ÂÇÏ¸é ¾î·Á¿òÀ» ±Øº¹ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

ÇѾç´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
02-2290-8114
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

ÇѾç´ëÇб³º´¿øÀº 1972³â °³¿ø ÀÌÈÄ, »ç¶ûÀÇ ½Çõ Á¤½ÅÀ» ¹ÙÅÁÀ¸·Î ÀÇ·áÀÇ ÇѰ迡 µµÀüÇϸç, Çõ½ÅÀûÀÎ ¼º°ú¸¦ ÀÌ·ï¿Ô½À´Ï´Ù. ·ù¸¶Æ¼½º ¹× ½Å°æ°èÁúȯ Ä¡·áÀÇ ¼±µµ º´¿ø°ú ÁßÁõ ¾ÏÁúȯ µî¿¡ ÃֽеðÁöÅÐ Çõ½Å ±â¼ú°ú ¿¬±¸Á߽ɺ´¿øÀ¸·Î¼­ AI, ºòµ¥ÀÌÅÍ µîÀ» Ȱ¿ëÇÑ ÀÓ»ó ¿¬±¸¸¦ °­È­ÇÏ¸ç ¹Ì·¡ ÀÇÇÐÀ» À̲ø°í ÀÖ½À´Ï´Ù.

ÇѾç´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ¼ºµ¿±¸ ¿Õ½Ê¸®·Î 222-1

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä